International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all regions and industry verticals to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
2022-2027:
The latest report by IMARC Group, titled “ Idiopathic Pulmonary Fibrosis Treatment Market: Global Industry Trends, Share, Size, Growth, Opp ortunity and Forecast 2022-2027 ,” finds that the global idiopathic pulmonary fibrosis treatment market reached a value of US$ 3,278 Million in 2021.
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease that causes scarring of the lungs, reducing their oxygen delivering capacity. The chronic lung disease is progressive and irreversible in nature as it continuously impacts the functioning of the lungs. It causes difficulty in breathing and does not provide sufficient oxygen to different body parts. IPF can be diagnosed through chest imaging studies, lung biopsies, pulmonary function tests, and antibody tests. Thetreatment includes nintedanib and pirfenidone-based drugs that aid in lung functioning and minimize the risk of acute respiratory deterioration. They are also offered along with oxygen therapy and palliative care, which improve the chances of recovery and provide comfort to the patient.
Request for a PDF sample of this report: https://www.imarcgroup.com/idiopathic-pulmonary-fibrosis-treatment-market/requestsample
The market is primarily driven by the rising geriatric population,which is susceptible tolung disorders. Aging is considered the greatest risk factor for the development of IPF. Moreover, the growing prevalence of fibrotic diseases, owing to changing lifestyles and heavy consumption of nicotine products like cigarettes is also propelling the demand for IPF treatment. Besides this, major healthcare companies are extensively investing in the development and commercialization of novel drugs, especially in emerging economies, which is fueling the growth of the market.
The rising health consciousness among individuals regarding effective management strategies is also creating a positive outlook for the market. Furthermore, increasing healthcare expenditures and improving infrastructure arealso facilitating the market growth.
Looking forward, the market value is expected to reach US$ 5,268 Million by 2027, exhibiting a CAGR of 7.89% during the forecast period (2022-2027).
View Report TOC, Figures and Tables: https://www.imarcgroup.com/idiopathic-pulmonary-fibrosis-treatment-market
• AdAlta Pty Ltd.
• Angion Biomedica Corp.
• Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG)
• Bristol-Myers Squibb Company
• Cipla Inc.
• F. Hoffmann-La Roche AG (Roche Holding AG)
• Fibrogen Inc.
• Galapagos NV, Liminal BioSciences Inc.
• Medicinova Inc.
• Merck & Co. Inc.
• Novartis AG
• Vectura Group Plc.
1. How has the global idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
2. What has been the impact of COVID-19 on the global idiopathic pulmonary fibrosis treatment market? 3. What are the key regional markets? 4. What is the breakup of the market based on the drug class? 5. What is the breakup of the market based on the end user? 6. What are the various stages in the value chain of the industry? 7. What are the key driving factors and challenges in the industry? 8. What is the structure of the global idiopathic pulmonary fibrosis treatment market and who are the key players? 9. What is the degree of competition in the industry?
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
